| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2008, p. 2279-2282, Vol. 52, No. 6
0066-4804/08/$08.00+0 doi:10.1128/AAC.01620-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033,1 Arpida AG, Reinach, Switzerland2
Received 18 December 2007/ Returned for modification 12 March 2008/ Accepted 15 March 2008
Against 300 strains of pneumococci and 100 group A streptococci of differing β-lactam, macrolide, and quinolone resistance phenotypes, AR-709 was very active, with all MICs being
2 µg/ml. Furthermore, AR-709 was active against strains that were both susceptible and resistant to trimethoprim-sulfamethoxazole.
Published ahead of print on 24 March 2008.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |